Skip to content

Implantation of marker seeds into the prostate; to improve quality of radiotherapy delivery and to allow dose escalation for men with localised prostate cancer

Implantation of marker seeds into the prostate; to improve quality of radiotherapy delivery and to allow dose escalation for men with localised prostate cancer

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12607000335493
Enrollment
20
Registered
2007-06-22
Start date
2007-04-01
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This is a study of implantation of marker seeds into the prostate to assess the feasibility of using marker seeds to locate the prostate before daily radiotherapy treatment for men with localised prostate cancer. Who is it for? You can join this study if you are a man aged 50–80 years with localised prostate cancer and you are going to have radiation therapy. Trial details Participants will have three marker seeds inserted under local anaesthetic into the prostate before radiotherapy. The seeds are like small rods inserted into the prostate gland and act as ‘landmarks’ so radiotherapy can be given as accurately as possible. All participants will have radiotherapy for 7 weeks. During the 7 weeks of therapy, X-rays will be taken daily for the first 2 weeks to measure the position of the seeds. After that, X-rays will be taken twice a week for 5 weeks to continue to measure the position of the marker seeds. These seeds will stay in your prostate permanently.

Interventions

Nonrandomised study. Three marker seeds will be inserted into the prostate before radiation planning. Using sequential portal films, the seeds can be visualised and measurements will be performed to assess set-up errors over the course of radiation therapy. The marker seeds will stay in the prostate permanently. The course of radiation therapy will be 7 weeks.

Sponsors

Dr George Hruby
Lead SponsorIndividual

Study design

Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
Male
Age
50 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

all men with clinically localised prostate cancer consented for radiotherapy

Exclusion criteria

on anti-coagulants where ceasing the medications are a cardiovascular risk

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026